MEDICA 2024: Innovating Molecular Diagnostics to Drive Decentralized Infectious Disease Testing

On November 11, 2024, MEDICA 2024, the global healthcare event, was successfully held at the Düsseldorf Exhibition Center in Germany. Pluslife made a powerful debut with its innovative molecular POCT solutions, known for their accuracy, speed, affordability, and convenience. These solutions span respiratory, tuberculosis, and reproductive health diagnostics, aiming to revolutionize and decentralize infectious disease testing. Pluslife's solutions empower grassroots testing capabilities and bring a whole new experience to visitors at the event.

Respiratory Molecular POCT Solutions

Pluslife’s four-in-one respiratory molecular POCT product drew significant attention from healthcare professionals. Respiratory viruses like Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) have a major global health impact, causing millions of hospitalizations and heavy testing demands annually. However, frequent testing can burden primary healthcare facilities, communities, and homes.

Pluslife’s four-in-one respiratory test card, paired with the MiniDock portable nucleic acid amplification analyzer, allows for easy operation with just 1-2 minutes of setup. Simple enough for non-professionals to use after brief training, this solution meets the needs of grassroots healthcare. The product can identify four pathogens—COVID-19, Influenza A/B, and RSV—in 35 minutes, with accuracy comparable to laboratory PCR tests.

Decentralized Testing for Faster Diagnosis

Through decentralized testing, diagnostic and treatment capabilities are not limited to large hospitals but are also available in primary healthcare institutions or communities. This approach improves testing efficiency, enables timely responses to infectious disease threats, and enhances public health management capabilities, reducing the risk of disease transmission.

Innovative Tuberculosis Molecular Diagnostics

Pluslife also showcased its innovative tuberculosis molecular diagnostic products. Despite significant progress in global tuberculosis control, challenges such as a lack of diagnostic tools in high-burden regions remain. In response, we developed a handheld rapid tuberculosis molecular diagnostic tool. This product offers low-cost, high-sensitivity, and easy-to-use advantages, fulfilling the demand for decentralized applications. It is one of the few mature, low-cost rapid molecular diagnostic tools for tuberculosis globally, and has been highly recognized by international organizations such as the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND).

The product supports both sputum and tongue swab samples. The tongue swab option offers an easier testing solution for populations who struggle to provide sputum samples, expanding its applicability and further supporting global tuberculosis prevention and control efforts.

Reproductive Health and Pet Diagnostics

At MEDICA 2024, Pluslife also showcased innovative diagnostic products in reproductive health and pet diagnostics. Our reproductive health solutions focus on testing for STIs like HPV, providing affordable and high-performance diagnostic tools for low- and middle-income countries. These tools enhance early screening and prevention capabilities for sexually transmitted diseases.

In addition, we presented our molecular diagnostic solutions for common pet diseases, including canine and feline parvovirus, among other infectious diseases. These products not only improve the accuracy and efficiency of pet health monitoring but also provide reliable diagnostic support for veterinary clinics and pet hospitals.

Looking Ahead

The innovative solutions showcased by Pluslife garnered valuable partnership opportunities and feedback, which will guide our efforts in other critical areas. Our goal is to decentralize disease testing, ensuring that even the most remote and resource-limited areas can access advanced diagnostic tools, thereby providing better health protection. Through these efforts, we aim to continue playing an indispensable role in global healthcare and contribute to improving public health worldwide.